NCT06771674 2025-09-09
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Hookipa Biotech GmbH
Completed
Clinical Trials
11 trialsNCT06654999 2025-07-09
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
Skin Analytics Limited
Completed
NCT03467529 2024-02-08
OESOCiTy
Nantes University Hospital
Completed
NCT05839002 2023-05-03
Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT
Fudan University
Completed
NCT00530283 2019-10-21
PET-CT for Squamous Cell Carcinoma (SCC) of the Neck Nodes Unknown Primary Malignancy
AHS Cancer Control Alberta
Completed
NCT01142869 2017-05-08
An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Merck KGaA, Darmstadt, Germany
Terminated
NCT01075828 2014-08-29
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Merck KGaA, Darmstadt, Germany
Completed
NCT01075841 2014-07-02
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Merck KGaA, Darmstadt, Germany
Withdrawn
NCT01358097 2014-04-10
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
Icahn School of Medicine at Mount Sinai
Completed
NCT01853059 2013-05-15
FOFACT
Cambridge University Hospitals NHS Foundation Trust
Unknown
NCT01709448 2012-10-18
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
National Institute of Allergy and Infectious Diseases (NIAID)
Unknown